Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three cases of heterologous sarcomas of the uterus are presented. Two were mixed tumors; one was a lipoleiomyosarcoma; and one was an osteogenic sarcoma with leiomyosarcoma. The third was a rhabdomyosarcoma. These tumors are believed to behave more aggressively than mixed mesodermal tumors. Six months after initial diagnosis, the lipolieomyosarcoma had metastasized to a vertebra. Following radiation therapy, the metastases recurred at the same site. The rhabdomyosarcoma of the uterus produced lung metastases 4 months following surgery, and the patient died 14 months after initial diagnosis despite extensive chemotherapy. The patient with osteogenic sarcoma of the uterus with leiomyosarcoma had been treated with Adriamycin and is alive and well 1 year following initial diagnosis. The histogenesis of these tumors is reviewed.
 ...
PMID:Heterologous sarcomas of the uterus. 630 4

The primary site of metastasis of bone and soft tissue sarcoma is the lung. Control of these sarcomas depends upon the prevention and treatment of their pulmonary metastasis. The introduction of a chemotherapy consisting mainly of Adriamycin and high-dose methotrexate dramatically improved the prognosis of osteosarcoma. However the effectiveness of chemotherapy has not yet been duplicated in soft tissue sarcomas except some childhood sarcomas. We analyzed the clinical data for pulmonary metastasis of osteosarcomas and soft tissue sarcomas. Based on these analyses, we tried to clarify the nature of pulmonary metastasis of these sarcomas and to evaluate its response to treatment, that this would yield clues to future treatment of these sarcomas.
 ...
PMID:[Chemotherapy of advanced bone and soft tissue sarcoma]. 654 Oct 20

A unique case of a 15-year-old boy with complete paraplegia due to the compression of osteogenic sarcoma at the fourth thoracic vertebra is presented. Because of the difficulty of surgical treatment, he was treated merely by the arterial infusion of Adriamycin (doxorubicin) and systemic chemotherapy in conformity with the cyclophosphamide, Oncovin (vincristine), methotrexate, phenylalanine mustard, Adriamycin (doxorubicin) ( COMPADRI )-III regimen. The patient regained normal function, and has been disease-free without any neurologic deficit for 6 years. There appears to be some hope for cure using chemotherapy only in otherwise unpromising patients.
 ...
PMID:Osteogenic sarcoma of the fourth thoracic vertebra. Long-term survival by chemotherapy only. 658 74

Conventional treatment for high grade and large sarcomas uses a radical surgical approach, including amputation, in many patients. We evaluated a limb-sparing treatment approach using preoperative regional Adriamycin chemotherapy and rapid-fraction radiation therapy. Thirty patients with soft tissue or skeletal sarcoma were treated in a prospective, nonrandomized clinical trial to evaluate local disease control and limb salvage in these patients who would otherwise require amputation or face a high risk of local recurrence with surgical excision. Almost all patients had large tumors with grade III histologic findings. All patients had a three day intra-arterial regional chemotherapy infusion with Adriamycin (100 milligrams total dose), followed within ten days by rapid-fraction irradiation (3,000 rads over a two week period) prior to surgical excision of the tumor. The size and location of the sarcoma permitted only a marginal resection in one-half of the patients, while the remainder could be excised in a three dimensional en bloc manner. Almost all patients received post-operative systemic Adriamycin chemotherapy (450 milligrams per square meter given intravenously over a six month period). Two of six patients with significant wound complications later required amputation. Only one patient (3 per cent) has had a local recurrence of sarcoma develop after a mean follow-up of 22 months (range nine to 42 months), and 90 per cent of the patients have a useful extremity. The three year survival rate was 68 per cent for soft tissue sarcomas, compared with an expected survival rate of 38 per cent for published historical control studies. The patient with osteogenic sarcoma has a projected 83 per cent survival rate at 18 months after treatment. This multimodality approach is an effective treatment for local disease control in patients with high risk sarcoma. It permits limb salvage in most patients without compromising the survival rates.
 ...
PMID:Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. 658 4

The relationship between total surface antigen expression per cell (means) - measured by fluorescence-labelled monoclonal antibodies (fluorescence-histograms) and the distribution of cells in the cell cycle (DNA-histograms) and size-scattergrams (cell sorter FACS-IV) were analysed in drug treated unsynchronized and synchronized osteogenic sarcoma cells (2OS) in vitro. Drugs with various sites of action in the cell cycle were used. Adriamycin, Vindesine, in concentrations applied accumulate cells in G2 + M phase. Methotrexate arrests cells in the boundary of G1/S phase. Size-scattergram and DNA-histogram analysis have shown that the entrance of cells to the cell cycle is usually accompanied by an increase in the cells size and amount of their DNA. The size of the cells influenced antigenic expression much more than the distribution of the cells in the various cell cycle phases: in the bigger cells the expression per cell was more pronounced. The increase of antigen expression was the highest for Adriamycin and for Methotrexate treated cells. However, this increase was limited and never exceeded plus 50% in relation to the control. This relatively low difference resulted from the fact, that a given phase of the cell cycle included cells markedly heterogenic in respect of size and antigenic content. It was also shown that lower concentration of serum in culture medium and confluent growth of older cultures decrease surface antigen expression per cell.
 ...
PMID:Analysis of surface antigen expression per cell of human osteogenic sarcoma cells by fluorescence-labelled monoclonal antibodies. 659 41

Twelve consecutive patients with osteosarcoma who were without evidence of metastases were treated with Adriamycin and cis-platinum in an adjuvant fashion. The primary lesion was in the distal femur in five patients, proximal tibia in three, and one each in the proximal femur, proximal humerus, sacrum, and a previously irradiated orbit. Surgery consisted of amputation in eight, limb-salvage procedures in two, and regional resections in the patients with orbital and sacral lesions. Postoperatively, Adriamycin at 30 mg/m2/d, for three days alternated every three weeks with cis-platinum, 100 mg/m2, once daily or 60 mg/m2/d, for two days i.v. drip forced i.v. fluid diuresis. Adriamycin was given to a total dose of 540 mg/m2. Ten of 12 patients remain continually disease-free with a median time on study of 23+ months (range 12+-41+ months). Local recurrences, without evidence of metastatic disease, occurred in the patient with the orbital lesion and the patient who underwent the regional resection for the lesion of the proximal humerus at 20 and 17 months from diagnosis, respectively. Nine patients are off all chemotherapy from 6+ to 33+ months (median 22+ months). Administration of cis-platinum was limited to eight courses because of renal and ototoxicity. Despite appreciable toxicity, this chemotherapeutic regimen appears to be a highly effective adjuvant in the management of primary nonmetastatic osteosarcoma.
 ...
PMID:Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. 693 69

An 18-year-old man had had an osteogenic sarcoma of the distal tibia at age 16. Below-knee amputation was carried out and followed by adjuvant chemotherapy with Adriamycin, vincristine, methotrexate, Cytoxan, and melphalan. One month after termination of chemotherapy, he died suddenly while playing tennis. Documented ventricular fibrillation was unresponsive to cardiopulmonary resuscitation. Myocardial fibrosis ("cardiomyopathy") was the only significant anatomic finding at autopsy. The occurrence of sudden death without antecedent cardiac failure may have been related to strenuous physical activity in this patient who had received combined adjuvant chemotherapy.
 ...
PMID:Sudden cardiac death following adriamycin therapy. 694 Jun 49

Adriamycin was administered intraarterially and the tumor was irradiated at a total focal dose of 3600 rad in the preoperational period in 25 children suffering from osteogenic sarcoma. Histological examinations of the tumors revealed marked necrobiotic, necrotic and sclerotic changes. Within 2 months after the beginning of the therapy the number of tumor cells decreased, they were localized predominantly in the peripheral parts of the extraosseal component. Later in the same areas new generations of tumor cells were found. In 3 cases tumor cells were completely absent. The results suggest the efficacy of adriamycin in combination with radiation therapy in treatment of osteogenic sarcoma.
 ...
PMID:[Morphological characteristics of osteogenic sarcoma after chemo-and radiotherapy]. 694 73

One hundred-twenty-four patients with this rare and special variant of osteogenic sarcoma were treated at Memorial Sloan-Kettering Cancer Center from 1921 through 1979, representing 11% of all of osteogenic sarcomas. The lesions were predominantly lytic, destructive tumors with only minimal sclerosis on roentgenograms and soft as well as cystic on gross examination. Histologically, aneurysmally dilated spaces lined or traversed by sarcoma cells producing osteoid were noted. The differential diagnosis both radiographically and histologically included several benign lesions like aneurysmal bone cyst and giant cell tumor, among many others. It was found that telangiectatic osteogenic sarcoma is relatively frequent in the femoral diaphysis and in the distal end of the femur. Twenty-nine percent of the patients present with pathologic fracture, or this develops later. Age and sex distribution, or clinical signs or symptoms were those of ordinary osteogenic sarcomas. No differences in survival rates were found in lesions that were purely lytic or those with minimal sclerosis. Similarly, no differences in survival were noted when comparing patients with telangiectatic or ordinary osteogenic sarcoma. As a matter of fact, definite increase in survival was found in patients treated since 1975 with preoperative multidrug chemotherapy employing high-dose methotrexate. Adriamycin, and the combination of bleomycin, cyclophosphamide, and dactinomycin.
 ...
PMID:Telangiectatic osteogenic sarcoma: a clinicopathologic study of 124 patients. 695 Aug 2

Following amputation of a limb for osteosarcoma, the tumour was serially transferred to nude mice. The rate of growth was determined and the inhibitory effect of Cyclophosphamide, Adriamycin and 5-Fluorouracil was assessed in three separate experimental animal groups. In the tumour studied. Cyclophosphamide produced the greatest inhibition of tumour growth, mitotic index and cytokinetic studies. The technique may be helpful in screening the sensitivity of other types of human malignant tumour.
 ...
PMID:Screening test of anticancer drugs on human osteosarcoma heterotransplanted in nude mice. 696 90


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>